Leonardo V Riella1, Kassem Safa, Jude Yagan, Belinda Lee, Jamil Azzi, Nader Najafian, Reza Abdi, Edgar Milford, Helen Mah, Steven Gabardi, Sayeed Malek, Stefan G Tullius, Colm Magee, Anil Chandraker. 1. 1 Schuster Family Transplantation Research Center, Renal Division, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA. 2 Division of Transplant Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA. 3 Department of Nephrology, Beaumont Hospital, Dublin, Ireland. 4 Address correspondence to: Anil Chandraker, MD, Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, 221 Longwood Ave, Boston MA 02115.
Abstract
BACKGROUND: More than 30% of potential kidney transplant recipients have pre-existing anti-human leukocyte antigen antibodies. This subgroup has significantly lower transplant rates and increased mortality. Desensitization has become an important tool to overcome this immunological barrier. However, limited data is available regarding long-term outcomes, in particular for the highest risk group with a positive complement-dependent cytotoxicity crossmatch (CDC XM) before desensitization. METHODS: Between 2002 and 2010, 39 patients underwent living-kidney transplantation across a positive CDC XM against their donors at our center. The desensitization protocol involved pretransplant immunosuppression, plasmapheresis, and low-dose intravenous immunoglobulin±rituximab. Measured outcomes included patient survival, graft survival, renal function, rates of rejection, infection, and malignancy. RESULTS: The mean and median follow-up was 5.2 years. Patient survival was 95% at 1 year, 95% at 3 years, and 86% at 5 years. Death-censored graft survival was 94% at 1 year, 88% at 3 years, and 84% at 5 years. Uncensored graft survival was 87% at 1 year, 79% at 3 years, and 72% at 5 years. Twenty-four subjects (61%) developed acute antibody-mediated rejection of the allograft and one patient lost her graft because of hyperacute rejection. Infectious complications included pneumonia (17%), BK nephropathy (10%), and CMV disease (5%). Skin cancer was the most prevalent malignancy in 10% of patients. There were no cases of lymphoproliferative disorder. Mean serum creatinine was 1.7±1 mg/dL in functioning grafts at 5 years after transplantation. CONCLUSION: Despite high rates of early rejection, desensitization in living-kidney transplantation results in acceptable 5-year patient and graft survival rates.
BACKGROUND: More than 30% of potential kidney transplant recipients have pre-existing anti-human leukocyte antigen antibodies. This subgroup has significantly lower transplant rates and increased mortality. Desensitization has become an important tool to overcome this immunological barrier. However, limited data is available regarding long-term outcomes, in particular for the highest risk group with a positive complement-dependent cytotoxicity crossmatch (CDC XM) before desensitization. METHODS: Between 2002 and 2010, 39 patients underwent living-kidney transplantation across a positive CDC XM against their donors at our center. The desensitization protocol involved pretransplant immunosuppression, plasmapheresis, and low-dose intravenous immunoglobulin±rituximab. Measured outcomes included patient survival, graft survival, renal function, rates of rejection, infection, and malignancy. RESULTS: The mean and median follow-up was 5.2 years. Patient survival was 95% at 1 year, 95% at 3 years, and 86% at 5 years. Death-censored graft survival was 94% at 1 year, 88% at 3 years, and 84% at 5 years. Uncensored graft survival was 87% at 1 year, 79% at 3 years, and 72% at 5 years. Twenty-four subjects (61%) developed acute antibody-mediated rejection of the allograft and one patient lost her graft because of hyperacute rejection. Infectious complications included pneumonia (17%), BK nephropathy (10%), and CMV disease (5%). Skin cancer was the most prevalent malignancy in 10% of patients. There were no cases of lymphoproliferative disorder. Mean serum creatinine was 1.7±1 mg/dL in functioning grafts at 5 years after transplantation. CONCLUSION: Despite high rates of early rejection, desensitization in living-kidney transplantation results in acceptable 5-year patient and graft survival rates.
Authors: Christopher K Burghuber; Miriam Manook; Brian Ezekian; Adriana C Gibby; Frank V Leopardi; Minqing Song; Jennifer Jenks; Frances Saccoccio; Sallie Permar; Alton B Farris; Neal N Iwakoshi; Jean Kwun; Stuart J Knechtle Journal: Am J Transplant Date: 2018-09-17 Impact factor: 8.086
Authors: Rosalie A Poldervaart; Mirjam Laging; Tessa Royaards; Judith A Kal-van Gestel; Madelon van Agteren; Marry de Klerk; Willij Zuidema; Michiel G H Betjes; Joke I Roodnat Journal: J Transplant Date: 2015-09-02
Authors: Renata von Glehn Ponsirenas; Helena B Cazarote; Stanley de Almeida Araújo; David Campos Wanderley; Silvia Shimakura; Joana S Valdameri; Fabiana L C Contieri; Cristina C Q C von Glehn; Michelle F Susin; Vanessa Santos Sotomaior Journal: Transplant Direct Date: 2018-08-22
Authors: Tomas Lorant; Mats Bengtsson; Torsten Eich; Britt-Marie Eriksson; Lena Winstedt; Sofia Järnum; Yvonne Stenberg; Anna-Karin Robertson; Kristina Mosén; Lars Björck; Lars Bäckman; Erik Larsson; Kathryn Wood; Gunnar Tufveson; Christian Kjellman Journal: Am J Transplant Date: 2018-04-17 Impact factor: 8.086
Authors: Sebastiaan Heidt; Geert W Haasnoot; Marissa J H van der Linden-van Oevelen; Frans H J Claas Journal: Front Immunol Date: 2021-06-25 Impact factor: 7.561
Authors: Jong Cheol Jeong; Enkthuya Jambaldorj; Hyuk Yong Kwon; Myung-Gyu Kim; Hye Jin Im; Hee Jung Jeon; Ji Won In; Miyeun Han; Tai Yeon Koo; Junho Chung; Eun Young Song; Curie Ahn; Jaeseok Yang Journal: Medicine (Baltimore) Date: 2016-02 Impact factor: 1.889